| Bioactivity | Elinogrel (PRT060128) is a potent, direct acting, competitive, and reversible platelet P2Y12 antagonist (IC50=20 nM). It is orally and intravenously available and has potent antiplatelet effects[1]. | ||||||||||||
| Target | IC50: 20 nM (P2Y12) | ||||||||||||
| Name | Elinogrel | ||||||||||||
| CAS | 936500-94-6 | ||||||||||||
| Formula | C20H15ClFN5O5S2 | ||||||||||||
| Molar Mass | 523.95 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Angiolillo DJ, et al. Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudyfrom the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary int [2]. Jacobson KA, et al. Pharmacochemistry of the platelet purinergic receptors. Purinergic Signal. 2011 Sep;7(3):305-24. |
Elinogrel
CAS: 936500-94-6 F: C20H15ClFN5O5S2 W: 523.95
Elinogrel (PRT060128) is a potent, direct acting, competitive, and reversible platelet P2Y12 antagonist (IC50=20 nM). It
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.